Patients with advanced BRCA-mutated breast cancer found no overall survival benefit with talazoparib
ABSTRACT: CTO71
New data from the Phase III EMBRACA trial led by researchers at The University of Texas MD Anderson Cancer Center found the PARP inhibitor talazoparib did not demonstrate a statistically significant overall survival (OS) benefit for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes. Most patients included in the study went on to receive subsequent systemic therapies, which...
MD Anderson genetics expert Guillermina Lozano elected to American Academy of Arts and Sciences
Guillermina Lozano, Ph.D., chair of Genetics at The University of Texas MD Anderson Cancer Center, has been elected as...